Cannabidiol (CBD) and Δ(9)-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial

INTRODUCTION: Insomnia is a highly prevalent and costly condition that is associated with increased health risks and healthcare utilisation. Anecdotally, cannabis use is frequently reported by consumers to promote sleep. However, there is limited research on the effects of cannabis on sleep and dayt...

Descripción completa

Detalles Bibliográficos
Autores principales: Suraev, Anastasia, Grunstein, Ronald R, Marshall, Nathaniel S, D'Rozario, Angela L, Gordon, Christopher J, Bartlett, Delwyn J, Wong, Keith, Yee, Brendon J, Vandrey, Ryan, Irwin, Chris, Arnold, Jonathon C, McGregor, Iain S, Hoyos, Camilla M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Pharmacology and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239553/
https://www.ncbi.nlm.nih.gov/pubmed/32430450
http://dx.doi.org/10.1136/bmjopen-2019-034421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239553/
https://www.ncbi.nlm.nih.gov/pubmed/32430450
http://dx.doi.org/10.1136/bmjopen-2019-034421

Ejemplares similares